Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer

Uehara, Masahiro; Kinoshita, Takayuki; Hojo, Takashi; Akashi‐Tanaka, Sadako; Iwamoto, Eriko; Fukutomi, Takashi

doi:10.1007/s10147-008-0773-3

Cited by 107 publications

(59 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are in accord with other articles published previously by our group with a smaller number of patients and shorter follow-up (16,18,26,27 ). Other studies have shown a shorter DFS and OS in patients with high values of these markers, whereas others report conflicting data (1,2,6,9,10,(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27). The reasons for these discrepancies are difficult to explain, but are possibly related to the number of patients and the length of follow-up.…”

Section: Discussionsupporting

confidence: 89%

“…Several groups have reported a relationship between carcinoembryonic antigen (CEA) 7 and/or carbohydrate antigen 15.3 (CA 15.3) positivity and tumor size or nodal involvement, whereas others have failed to confirm such a relationship (1,2,(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23). Further study of the prognostic value of tumor markers appears to be necessary (1,2,(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer

Molina¹,

Augé²,

Farrús³

et al. 2010

Clinical Chemistry

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

mentioning

confidence: 99%

Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer

Molina¹,

Augé²,

Farrús³

et al. 2010

Clinical Chemistry

View full text Add to dashboard Cite

show abstract

“…Similar to cadherins, Ig-SF CAMs can be cleaved by metalloproteinases, which causes the release of soluble fragments that have distinct biological functions. Studies on Ig-SF CAMs in breast cancer have identified several members that are up-regulated during cancer progression and are potentially associated with an unfavorable prognosis: intercellular CAM 1 (ICAM-1) and its soluble fragment (sICAM-1) [116], L1 protein [117], epithelial cell adhesion molecule (EpCAM) [118][119][120], soluble VCAM-1 [116,121], and carcinoembryonic antigen (CEA) [122]. However, little is known on the regulatory mechanisms and functional significance of these Ig-SF CAMs during breast cancer metastasis, with the exception of ICAM-1, where some studies have suggested a role in breast cancer metastasis.…”

Section: Ig-sf Camsmentioning

confidence: 99%

Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets

Feng

2011

Breast Cancer Res Treat

115

View full text Add to dashboard Cite

Metastasis is responsible for the majority of breast cancer-related deaths. The metastatic spread of cancer cells is a complicated process that requires considerable flexibility in the adhesive properties of both tumor cells and other interacting cells. Cell adhesion molecules (CAMs) are membrane receptors that mediate cell-cell and cell-matrix interactions, and are essential for transducing intracellular signals responsible for adhesion, migration, invasion, angiogensis, and organ-specific metastasis. This review will discuss the recent advances in our understanding on the biological functions, signaling mechanisms, and therapeutic potentials of important CAMs involved in breast cancer metastasis.

show abstract

“…Several circulating tumor protein biomarkers frequently used clinically, such as carcinoembryonic antigen and carbohydrate antigen 15-3, have been noted to have low preoperative diagnostic sensitivity, thus indicating their limited use for detecting early-stage breast cancer (73 ). Over the past decade, certain mRNAs have been reported as circulating in serum/plasma from cancer patients (74,75 ).…”

Section: Potential Use Of Mirnas As Biomarkers For Breast Cancer Extrmentioning

confidence: 99%

Intracellular and Extracellular MicroRNAs in Breast Cancer

et al. 2011

View full text Add to dashboard Cite

BACKGROUND Successful treatment of breast cancer is enhanced by early detection and, if possible, subsequent patient-tailored therapy. Toward this goal, it is essential to identify and understand the most relevant panels of biomarkers, some of which may also have relevance as therapeutic targets. METHODS We critically reviewed published literature on microRNAs (miRNAs) as relevant to breast cancer. SUMMARY Since the initial recognition of the association of miRNAs with breast cancer in 2005, studies involving cell lines, in vivo models, and clinical specimens have implicated several functions for miRNAs, including suppressing oncogenesis and tumors, promoting or inhibiting metastasis, and increasing sensitivity or resistance to chemotherapy and targeted agents in breast cancer. For example, miR-21 is overexpressed in both male and female breast tumors compared with normal breast tissue and has been associated with advanced stage, lymph node positivity, and reduced survival time. miR-21 knock-down in cell-line models has been associated with increased sensitivity to topotecan and taxol in vitro and the limitation of lung metastasis in vivo. Furthermore, the discovery of extracellular miRNAs (including miR-21), existing either freely or in exosomes in the systemic circulation, has led to the possibility that such molecules may serve as biomarkers for ongoing patient monitoring. Although additional investigations are necessary to fully exploit the use of miRNAs in breast cancer, there is increasing evidence that miRNAs have potential not only to facilitate the determination of diagnosis and prognosis and the prediction of response to treatment, but also to act as therapeutic targets and replacement therapies.

show abstract

Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer

Abstract: There was a positive correlation between CEA levels and CA 15-3 levels and patient prognosis. Thus, the levels of these tumor markers may help to determine prognosis in breast cancer patients.

Cited by 107 publications

References 15 publications

Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer

Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer

Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets

Intracellular and Extracellular MicroRNAs in Breast Cancer

Contact Info

Product

Resources

About